Skip to main content

Table 2 Current clinical trials (at clinicaltrials.gov) evaluating the combination of RT with immune checkpoint inhibitors

From: The rationale for including immune checkpoint inhibition into multimodal primary treatment concepts of head and neck cancer

Clinical setting Clinical trial Drug Combination
Resectable locally advanced SCCHN NCT02641093 phase II Pembrolizumab Adjuvant RT/RCT
NCT02296684 phase II Pembrolizumab Adjuvant RT/RCT
Locally advanced SCCHN NCT01935921 phase I Ipilimumab Definitive RT + cetuximab
Intermediate/High risk locally advanced SCCHN NCT01860430 phase Ib Ipilimumab Definitive RT + cetuximab
Locally advanced SCCHN NCT02586207 phase I Pembrolizumab Definitive RT + CDDP
locally advanced laryngeal carcinoma NCT02759575 phase I/II Pembrolizumab Definitive RT + CDDP
Intermediate/High risk locally advanced SCCHN NCT02764593 phase I Nivolumab Definitive RT, RT+ CDDP, RT + cetuximab
Phase III Nivolumab Definitive RT + CDDP
locoregional inoperable recurrence or second primary SCCHN NCT02289209 phase II Pembrolizumab Reirradiation
Advanced metastatic disease (multicohort) NCT02303990 phase I Pembrolizumab RT
Brain metastasis (multicohort) NCT02669914 phase II Durvalumab Stereotactic radiosurgery
  1. RT radiotherapy, CDDP cisplatin
Back to article page

Cancers of the Head & Neck

ISSN: 2059-7347

Contact us